



(12) Oversettelse av endret
europeisk patentskrift
Etter innsigelse

(11) NO/EP 2886108 B2

NORGE (19) NO
(51) Int Cl.

A61K 9/46 (2006.01)

A61K 9/20 (2006.01)

A61K 9/00 (2006.01)

A61K 31/58 (2006.01)

Patentstyret

(45)	Oversettelse publisert	2019.06.11
(80)	Dato for Den Europeiske Patentmyndighets publisering av det meddelte patentet	2019.02.06
(45)	Avgjørelse innsigelse i EPO	2022.11.02
	Avgjørelse innsigelse i Norge	2023.03.13
(86)	Europeisk søknadsnr	13199278.6
(86)	Europeisk innleveringsdag	2013.12.23
(87)	Den europeiske søknadens Publiseringsdato	2015.06.24
(84)	Utpekte stater	AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR
(73)	Innehaver	Dr. Falk Pharma GmbH, Leinenweberstrasse 5, 79108 Freiburg, Tyskland
(72)	Oppfinner	Greinwald, Roland, Jakob-Otter-Str. 2, 79341 Kenzingen, Tyskland Müller, Ralph, Neuntöterweg 8, 79111 Freiburg, Tyskland Pröls, Markus, Johann-von-Weerth-Str. 11, 79100 Freiburg/Breisgau, Tyskland Wilhelm, Rudolf, Feuerkirschenweg 2A, 76476 Bischweier, Tyskland
(74)	Fullmektig	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54)	Benevnelse	Optimised pharmaceutical formula for the treatment of inflammatory changes of the esophagus
(56)	Anførte publikasjoner	EP-A1- 1 595 533, US-A1- 2007 020 330, US-A1- 2010 034 894, EP-A1- 2 151 235 US-A1- 2011 123 460 DR. SCHLEUNIGER: "Key factors influencing measured tablet hardness", Pharmatron, 2011, pages 1-5, Retrieved from the Internet: URL: https://www.pharmaceutical-networking.com/wp-content/uploads/2012/06/Key-Factors-Influencing-Measured-Tablet-Hardness.pdf KRISHNA et al.: "Treatment of Eosinophilic Esophagitis: Oral Viscous Budesonide Superior to Swallowed Fluticasone Spray?", Gastroenterol Hepatol., vol. 7, no. 1, January 2011 (2011-01), pages 55-59, DOHIL et al.: Gastroenterology, vol. 139, no. 2, 24 July 2010 (2010-07-24) , pages 418-429. e1, TAYEBI et al.: "Formulation and Evaluation of a Novel Matrix-Type Orally Disintegrating Ibuprofen Tablet", Iran J Pharm Res, vol. 10, no. 3, 2011, pages 469-479, Rowe et al.: "HANDBOOK OF PHARMACEUTICAL EXCIPIENTS", 2006, London pages 53-55, 742-743,

11

") 0 1 ' / 2 2 ! (

11

$$(/ \quad ' ($$

2 + '

) "

& 5 ! +!

7 " * \$' * 6* " . - "

- " 6

) 9

11

#

!) %

%

•

! ;

+ " < %

$$: 4 \quad " = \quad " " ! ! + (; ; "$$

? > @

!

"#

")

- 1

"#

!

"

<

".

++

2 (

"

<

\$

!

" 5

" 6

!

" #

"

"

" "

"!

+"

"

"

"

"

<

"

#

B

B (B

&

5

" " " "

"

! 6

"#

: ;

%

"6

"

+ 5

0 , # + . & 1

"

" "

", \$

"<

! " " C 2" (" C

"

<

")

C " (" C "

<

" !C " ! !C "

! # 9

",

"4

% (' !C

! ' C ")

"#

!

"

1

C "

+ #

"#

,

"

#

"#

"

!

5

"

&_____D

)

+

\$

"

)

")

!

",

"

Table 3: Lacking stability of budesonide 1 mg effervescent tablets with modified composition

	4	! E - / C					
	)	+		'			(
- 8 F C G	' "	'" (	"	'"	' "'	' "	'! " (
4 F C G	H "	" +	"	"	"	" !	" +

	4	+ E - / ! C			
	)	+		'	
- 8 F C G	' "	"	" 2	'" 2	' "
4 F C G	H "	H "	"'	"	" +

!) '2 " "

& 2 D

- 6 D

) 2 \$))

/ / /

8" 6 > 6 @ "#

#

: ; H / ≥

! @ " " 2 ; %

" <

/ "

8

"#

4 " "

!

& D

#

! "

"#

! : 6"

!

"#

"

!

" #

#\$

% &

&

'

()

* + * , %

! \$ *

!

& " -

& -

. " -

. -

- -

*

" #

*

%

. !

!

#

\$

*

!

%

)

#&

#

\$

*

%

#\$

*

8.

karakterisert ved at

9.

10.

Figure 1: Mean Load with Eosinophils in the respective Esophagus Segment




Figure 2: Mean Total Endoscopic Intensity Score

